Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials

By sjmartinez • April 19, 2024

Lebwohl M, Warren RB, Sofen H, Imafuku S, Paul C, Szepietowski JC, Spelman L, Passeron T, Vritzali E, Napoli A, Kisa RM, Buck A, Banerjee S, Thaçi D, Blauvelt A. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. Br J Dermatol. 2024 Apr 17;190(5):668-679. doi: 10.1093/bjd/ljae014. PMID: 38226713.

Tags: Dermatology, Olive View DoM, Publications

An epigenetic clock for Xenopus tropicalis

Bennett R, Morselli M, Petrova K, Peshkin L, Pellegrini M. An epigenetic clock for Xenopus tropicalis. NPJ Aging. 2025 May 22;11(1):38. doi: 10.1038/s41514-025-00236-x. PMID: 40404700.

Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis

Li B, Elsten-Brown J, Li M, Zhu E, Li Z, Chen Y, Kang E, Ma F, Chiang J, Li YR, Zhu Y, Huang J, Fung[...]

Insights into early acne pathogenesis: Exploring intercellular dynamics and key dysregulated genes

Deng M, Farahani K, Agak GW. Insights into early acne pathogenesis: Exploring intercellular dynamics and key dysregulated genes. Cell Signal (Middlet). 2025;3(1):32-39. doi: 10.46439/signaling.3.053. PMID:[...]